Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS
CAMBRIDGE, Mass., May 19, 2022 -- Foghorn® Therapeutics Inc. , a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively... | May 19, 2022
Source: marketscreener.com